Mylab Discovery Solutions launched Mybox+ diagnostic device with range of important tests including Thyroid panel (T-3, T-4, TSH), Cardiac marker (Troponin), and biomarker (CRP, D-Dimer).
The introduction of MyBox+ and its Dry Luminescence technology represents a transformative step forward in the field of diagnostics. It empowers small labs and clinics, enabling them to offer a broader range of tests and improve patient care. This technology marks a departure from traditional liquid reagent-based testing methods, offering a game-changing solution for small labs and clinics that previously faced limitations in performing certain tests. Until now, many small labs had to rely on outsourcing these tests to larger facilities, which often resulted in delayed results and increased costs associated with sample transportation.
MyBox+ is a portable device powered by optical AI engines, to deliver highly accurate, rapid quantitative and qualitative results in clinical samples. The device can be used to conduct tests for 30+ diseases and can invaluable diagnostic tool that can be easily set up in small labs and centres.
Hasmukh Rawal, MD & Co-founder, Mylab said, “The launch of these Dry-LIA Test with MyBox+ represents our commitment to provide healthcare professionals with advanced tools to facilitate early diagnosis and better patient outcomes. These Tests utilise state-of-the-art dry luminescence technology, providing rapid and reliable results within minutes even at small centres. By bringing advanced testing capabilities to small labs, we aim to democratise diagnostic services, ensuring that critical tests are accessible to all, regardless of geographic location or facility size”.
